PROCEPT BioRobotics Corp
AQUA Surgical Robotics Inc. (NASDAQ: ASRS) is a surgical robotics company focused on developing and commercializing advanced robotic systems for minimally invasive urologic surgery. The company's website is www.aquasurgical.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PROCEPT BioRobotics Corp does
In the company’s own words
AQUA Surgical Robotics Inc. (NASDAQ: ASRS) is a surgical robotics company focused on developing and commercializing advanced robotic systems for minimally invasive urologic surgery. The company's website is www.aquasurgical.com.
The company develops, manufactures, and sells the AquaBeam Robotic System and the next-generation HYDROS Robotic System, both of which deliver Aquablation therapy, a proprietary image-guided robotic treatment for benign prostatic hyperplasia, or BPH. Aquablation therapy combines real-time multidimensional imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation to remove prostate tissue with precision and consistency. The systems are designed to deliver effective, safe, and durable outcomes independent of prostate size, shape, and surgeon experience.
BPH is the most common prostate disease, affecting approximately 40 million men in the United States. The company estimates its total addressable market opportunity at approximately $30 billion in the United States alone, with significant additional opportunity in international markets where BPH prevalence among men over 50 is similar to the United States.
As of December 31, 2025, the company had an installed base of 912 robotic systems globally, including 718 in the United States. The company generated revenue of $308.1 million for the year ended December 31, 2025, primarily from sales of robotic systems and single-use disposable handpieces. The company operates primarily through a direct sales organization in the United States targeting urologists and hospitals, with distribution partnerships in select international markets.
The company has developed a substantial clinical evidence base supporting Aquablation therapy, including nine clinical studies and over 150 peer-reviewed publications. Medicare coverage has been established in all 50 states, and the company estimates that approximately 95 percent of men in the United States have access to Aquablation therapy through commercial insurance coverage. The company is also investing in clinical research to support the use of Aquablation therapy for prostate cancer treatment through multiple investigational studies.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- SAN JOSE, CA
- Fiscal year end
- December
- CIK
- 1588978
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PROCEPT BioRobotics Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · PROCEPT BioRobotics Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PROCEPT BioRobotics Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PROCEPT BioRobotics Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PROCEPT BioRobotics Corp's last four quarterly filings that the numbers alone won't show?”